Study wrapper · #816
Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison.
Editor's note
This is an indirect treatment comparison (ITC) pitting oral semaglutide 25 mg against the oral small-molecule GLP-1 agonist orforglipron 36 mg for weight loss, stitched together from two separate trials (OASIS 4 and ATTAIN-1) rather than a head-to-head study. The population-adjusted analysis reported greater body-weight reduction with oral semaglutide (about 3 percentage points more) and notably fewer discontinuations, especially for gastrointestinal side effects. Readers should weight ITCs cautiously: comparing across trials — even with individual-patient-data anchoring and population adjustment — assumes the trials are similar enough to bridge, and unmeasured differences in populations, endpoints, and conduct can bias the result. The wide confidence interval on GI-discontinuation odds (up to 96) signals real imprecision. This is a sponsor-relevant comparison (a semaglutide manufacturer-affiliated author set) and, importantly, not a substitute for the head-to-head trial the authors themselves say is absent. Useful directional evidence on semaglutide, appropriately hedged.
Plain-language abstract
This study compared two weight-loss pills — oral semaglutide and a newer drug called orforglipron — in adults with overweight or obesity but without diabetes. Because no trial has tested the two drugs directly against each other, the researchers used a statistical technique to compare results from two separate trials, adjusting for differences in the patients so the comparison would be fairer. In this indirect comparison, oral semaglutide was linked to slightly greater weight loss (about 3 percentage points more) and to fewer people quitting the drug because of side effects, particularly stomach-and-gut side effects. An important limitation is that comparing across two different trials is less reliable than a single head-to-head study; hidden differences between the trials could tilt the results, and some of the numbers had wide uncertainty ranges. The authors are clear that this analysis is meant to fill a gap until a proper direct comparison is done. So this offers a useful hint that oral semaglutide may edge out orforglipron on weight loss and tolerability, but not a firm conclusion.